These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 25431348)
1. The Use of Biologic Therapies in Uveitis. Schwartzman S; Schwartzman M Clin Rev Allergy Immunol; 2015 Dec; 49(3):307-16. PubMed ID: 25431348 [TBL] [Abstract][Full Text] [Related]
2. Advancements in the management of uveitis. Schwartzman S Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):304-315. PubMed ID: 27886802 [TBL] [Abstract][Full Text] [Related]
3. The use of biologic agents in the management of uveitis. Trivedi A; Katelaris C Intern Med J; 2019 Nov; 49(11):1352-1363. PubMed ID: 30582273 [TBL] [Abstract][Full Text] [Related]
4. Current and future treatments for Behçet's uveitis: road to remission. Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309 [TBL] [Abstract][Full Text] [Related]
5. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Benitah NR; Sobrin L; Papaliodis GN Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178 [TBL] [Abstract][Full Text] [Related]
6. Biologic therapy for Behçet's uveitis: a systematic review. Uke P; Gorodkin R; Beare N Br J Ophthalmol; 2020 Aug; 104(8):1045-1051. PubMed ID: 31676596 [TBL] [Abstract][Full Text] [Related]
8. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Thomas AS Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945 [TBL] [Abstract][Full Text] [Related]
9. Biologics in the treatment of uveitis. Imrie FR; Dick AD Curr Opin Ophthalmol; 2007 Nov; 18(6):481-6. PubMed ID: 18163000 [TBL] [Abstract][Full Text] [Related]
10. Biologic Therapies: Anti-Tumor Necrosis Factor-α, Anti-Interleukins, Rituximab and Others. Bhatt N; Tucker W; Sen HN; Nussenblatt RB Dev Ophthalmol; 2016; 55():252-64. PubMed ID: 26501216 [TBL] [Abstract][Full Text] [Related]
11. TNF inhibition for ophthalmic indications: current status and outlook. Rifkin LM; Birnbaum AD; Goldstein DA BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177 [TBL] [Abstract][Full Text] [Related]
12. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Pasadhika S; Rosenbaum JT Biologics; 2014; 8():67-81. PubMed ID: 24600203 [TBL] [Abstract][Full Text] [Related]
14. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359 [TBL] [Abstract][Full Text] [Related]